- Home
- INDV vs ARQT Comparison
INDV vs ARQT Comparison
Compare INDV & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INDV | ARQT |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.3B |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INDV | ARQT |
|---|---|---|
| Price | $33.62 | $28.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $25.83 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 06-08-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 102.13 | 88.79 |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $1,188,000,000.00 | $376,072,000.00 |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | N/A | $30.59 |
| P/E Ratio | $39.56 | ★ N/A |
| Revenue Growth | 8.69 | ★ 91.34 |
| 52 Week Low | $8.34 | $11.86 |
| 52 Week High | $38.00 | $31.77 |
Technical Indicators
Market Signals| Indicator | INDV | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 58.29 |
| Support Level | $33.15 | $28.07 |
| Resistance Level | $36.07 | $30.93 |
| Average True Range (ATR) | 1.18 | 1.46 |
| MACD | -0.08 | 0.20 |
| Stochastic Oscillator | 42.95 | 86.64 |
Price Performance
Historical ComparisonAbout INDV Indivior PLC
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.